Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolMatthew R. Sydes, Nicholas D. James, Melissa Spears et al.|Annals of Oncology|2018Cited by 252
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)Nicholas D. James, Jacob Tanguay, David P. Dearnaley et al.|International Journal of Cancer|2022Cited by 79
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI‐mediated basophil activation by a tumour‐specific IgE antibody to evaluate the risk of type I hypersensitivitySarah Maria Rudman, Sophia N. Karagiannis, Debra H. Josephs et al.|Clinical & Experimental Allergy|2011Cited by 41
1868P Real-world safety of the 6-weekly pembrolizumab regimen in cancer patients treated in South East LondonMatthaios Kapiris, A. L. Georgiou, L. Cain et al.|Annals of Oncology|2021Cited by 0